IGF-1 protects tubular epithelial cells during injury via activation of ERK/MAPK signaling pathway

Zengbin Wu, Yang Yu, Lei Niu, Aihua Fei & Shuming Pan

Injury of renal tubular epithelial cells can induce acute renal failure and obstructive nephropathy. Previous studies have shown that administration of insulin-like growth factor-1 (IGF-1) ameliorates the renal injury in a mouse unilateral ureteral obstruction (UUO) model, whereas the underlying mechanisms are not completely understood. Here, we addressed this question. We found that the administration of IGF-1 significantly reduced the severity of the renal fibrosis in UUO. By analyzing purified renal epithelial cells, we found that IGF-1 significantly reduced the apoptotic cell death of renal epithelial cells, seemingly through upregulation of anti-apoptotic protein Bcl-2, at protein but not mRNA level. Bioinformatics analyses and luciferase-reporter assay showed that miR-429 targeted the 3′-UTR of Bcl-2 mRNA to inhibit its protein translation in renal epithelial cells. Moreover, IGF-1 suppressed miR-429 to increase Bcl-2 in renal epithelial cells to improve survival after UUO. Furthermore, inhibition of ERK/MAPK signaling pathway in renal epithelial cells abolished the suppressive effects of IGF-1 on miR-429 activation, and then the enhanced effects on Bcl-2 in UUO. Thus, our data suggest that IGF-1 may protect renal tubular epithelial cells via activation of ERK/MAPK signaling pathway during renal injury.

Obstructive nephropathy is a major cause of renal failure, the cellular and molecular mechanisms of which have been elucidated in the past years. Following urinary tract obstruction and tubular dilatation, upregulation of the intrarenal renin-angiotensin system, tubular apoptosis and macrophage infiltration of the interstitium all occur, followed by accumulation of interstitial fibroblasts through proliferation of resident fibroblasts and epithelial-to-mesenchymal transition (EMT) of renal tubular cells. Fibroblasts thus transform to myofibroblasts that induce excess deposition of the extracellular matrix in response to the cytokines, chemokines and other signaling molecules secreted by tubular and interstitial cells. Among these biological steps, injury and apoptotic cell death of renal epithelial cells are the initial process.

Insulin-like growth factor-1 (IGF-1) is a peptide growth factor produced by the collecting duct of the adult kidney, and its receptors are present in glomeruli and on the basolateral membrane of renal proximal tubular cells. The IGF-1R signaling pathway initiates with binding of IGF-1 to its cell-surface receptor IGF-1R to activate phosphatidylinositol-3 kinase (PI3K)/Akt or extracellular signal-regulated kinase (ERK)/mitogen-Activated Protein Kinase (MAPK) signaling pathway, to stimulate cell growth and proliferation, and to inhibit programmed cell death. Following ischemic injury, renal IGF-1 has been shown to decrease. The administration of exogenous IGF-1 has been shown to accelerate recovery from ischemic acute renal failure, possible through enhanced proliferation and reduced apoptosis of tubular epithelial cells. However, the exact mechanisms are not completely understood.

Cellular apoptosis is regulated by apoptosis activating proteins, e.g. Bid, Bak, Bad, and apoptosis suppressors, e.g. B-cell lymphoma 2 (Bcl-2). Bcl-2 is the founding member of the Bcl-2 family of regulator proteins that regulate cell death (apoptosis), by either inducing (pro-apoptotic) or inhibiting (anti-apoptotic) apoptosis.

Growing evidence has suggested that aberrant expression of microRNAs (miRNAs) plays a critical role in regulation of many proteins in pathological conditions, including renal injury. MiRNA is a class of non-coding small RNA of comprised of about 18–23 nucleotides, and regulate the gene expression at protein level, through their base-pairing with the 3′-untranslated region (3′-UTR) of the mRNA of the target gene. Among all miRNAs, miR-429 is a demonstrated miRNA that targets and regulates Bcl-2. However, its regulation by IGF-1 and its function on Bcl-2 in renal epithelial cells during injury has not been reported.

Department of Emergency, Xinhua Hospital, Shanghai Jiaotong University Medical College, Shanghai 200092, China. Correspondence and requests for materials should be addressed to S.P (email: shuming_pan16@126.com)
Here, we found that the administration of IGF-1 significantly reduced the severity of the renal fibrosis in a mouse unilateral ureteral obstruction (UUO) model. By analyzing purified renal epithelial cells, we found that IGF-1 significantly reduced the apoptotic cell death of renal epithelial cells, seemingly through upregulation of anti-apoptotic protein Bcl-2. Bioinformatics analyses and luciferase-reporter assay showed that miR-429 targeted the 3′-UTR of Bcl-2 mRNA to inhibit its protein translation in renal epithelial cells. Moreover, IGF-1 suppressed miR-429 to increase Bcl-2 in renal epithelial cells to improve survival after UUO. Furthermore, inhibition of ERK/MAPK signaling pathway in renal epithelial cells abolished the suppressive effects of IGF-1 on miR-429 activation, and then the enhanced effects on Bcl-2 in UUO.

Materials and methods

Protocol approval. All the experimental methods have been approved by the research committee at Xinhua Hospital at Shanghai Jiaotong University. All animal experiments were approved by the Institutional Animal Care and Use Committee at Xinhua Hospital at Shanghai Jiaotong University (Animal Welfare Assurance). All the experiments and methods were carried out in “accordance” with the approved guidelines. Surgeries were performed in accordance with the Principles of Laboratory Care, supervised by a qualified veterinarian.

The UUO model. Twelve week-old male C57/6 mice were subjected to left ureteral ligation, as has been previously described. Briefly, after anesthesia with sodium pentobarbital (40 mg/kg, ip) was given to the mice, and their left ureters were ligated with 6-0 silk sutures. The UUO mice were randomly divided into different groups, and were sacrificed at 3 or 14 days after surgery.

Cell isolation, culture and treatment. The mouse kidney was digested into single cells as has been described before. Briefly, the mouse kidney was decapsulated and chopped into small pieces of 2–3 mm of diameter, followed by 45 minutes’ digestion with 40 mg/dl collagenase (Sigma-Aldrich) in a 37 °C shaker at 200 rpm. The digestion appeared to be very complete, since most of the digests passed a 66 nm filter. The filtered kidney digests were then incubated with FITC-conjugated anti-E-cadherin (E-cad, Becton-Dickinson Biosciences, San Jose, CA, USA) for labeling of the renal epithelial cells. FITC-positive cells were sorted by flow cytometry. The sorted cells were either analyzed immediately or cultured in RPMI1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 15% fetal bovine serum (FBS, Sigma-Aldrich, St Louis, MO, USA), penicillin (100 μg/ml) and streptomycin (250 μg/ml) in a humidified chamber with 5% CO2 at 37°C. Recombinant human IGF1 (100 ng/ml) and ERK/MAPK-p42/p44 inhibitor PD98059 (10 μmol/l) were also purchased from Sigma-Aldrich.

Plasmids transfection. MiR-429-expressing, antisense of miR-429 (as-miR-429) and control null plasmids were all purchased from RiboBio Co., Ltd. (Guangzhou, China). All plasmid constructs also contain a GFP reporter. Transfection was performed with Lipofectamine 2000 reagent (Invitrogen). Transfected cells were purified by flow cytometry based on GFP.

Western blot. The protein was extracted from the purified or cultured cells, in RIPA lysis buffer (Sigma-Aldrich) supplemented with proteinase inhibitor (Roche, Nutley, NJ, USA). Protein concentration was determined using a BCA protein assay kit (Bio-rad, China), and whole lysates were mixed with 4× SDS loading buffer (Roche), heated, and then separated on SDS-polyacrylamide gels. The separated proteins were then transferred to a PVDF membrane. The membrane blots were done as routine. The signals were recorded using X-ray film. Primary antibodies were rabbit anti-Bcl-2, anti-ERK1/2, anti-phosphorylated ERK1/2 (pERK1/2) and anti-α-tubulin (Cell Signaling, San Jose, CA, USA). Secondary antibody is HRP-conjugated anti-rabbit (Jackson ImmunoResearch Labs, West Grove, PA, USA). Blotting images were representative from 5 repeats. The protein levels were first normalized to protein loading control, α-tubulin, and then normalized to the experimental controls. Densitometry of Western blots was quantified with NIH Image software (Bethesda, MD, USA).

Quantitative RT-PCR. Total RNA were extracted from isolated or cultured cells with miRNeasy mini kit (Qiagen, Hilden, Germany). Complementary DNA (cDNA) was prepared from 2 μg of total RNA using High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). RT-qPCR was done in triplicate with QuantiTect SYBR Green PCR Kit (Qiagen). All primers were purchased from Qiagen. The primer sequence for miR-429 detection is: Forward primer: 5′-UUUAAACUGUCGUAAACCCGU-3′; Reverse primer: 5′-UCUCGGAACGUCAGCUTT-3′. Data were analyzed using 2-ΔΔCt method for quantification of the relative mRNA expression levels. Values of genes were first normalized against α-tubulin, and then compared to the experimental controls.

MiRNA target prediction and 3′-UTR luciferase-reporter assay. MiRNAs targets were predicted using the algorithms TargetScan (https://www.targetscan.org). The Bcl-2 gene was input and then a list of miRNAs that target certain base pairs on Bcl-2 were shown in the map. The levels of these miRNAs in our experimental conditions were then examined. Only those that had a significant change by UUO with/without IGF-1 were used as candidates for further analyses. Luciferase-reporters were constructed using molecular cloning technology. Target sequences for Bcl-2 3′-UTR and Bcl-2 3′-UTR with a site mutation at miR-429 binding site (Bcl-2 3′-UTR mut) were purchased from Creative Biogene (Shirley, NY, USA). Purified renal epithelial cells were seeded in 24-well plates for 24 hours, after which they were co-transfected with 1 μg of Luciferase-reporter plasmids and miR-429-modified plasmids. Luciferase activities were evaluated using the dual-luciferase reporter gene assay kit (Promega, Beijing, China).

Apoptosis assay by flow cytometry. For analysis of cell proliferation, the cells were re-suspended at a density of 105 cells/ml in PBS. Double staining was performed for FITC-Annexin V and propidium iodide (PI)
a FITC Annexin V Apoptosis Detection Kit I (Becton-Dickinson Biosciences, San Jose, CA, USA), after which the cells were analyzed using FACSscan flow cytometer (Becton-Dickinson Biosciences) for determination of Annexin V+PI-apoptotic cells.

**Immunohistochemistry and quantification of degree of renal fibrosis.** Kidneys were removed, fixed in 10% neutral formalin, embedded in paraffin, sectioned at 3 μm thickness, and stained with Masson trichrome using routine procedures. Evaluation of renal fibrosis in each sample was performed based on 20 randomly selected fields per section, which were examined under ×400 magnification for assessment of the degree of renal fibrosis. The degree of renal fibrosis was scored in Masson-trichrome stained sections as the ratio of the positive stain area (blue) to that of the whole area (n = 20). Renal fibrosis was examined in each mouse and then averaged for the five mice from each group.

**Statistical analysis.** GraphPad Prism 6.0 (GraphPad Software, Inc. La Jolla, CA, USA) was used for statistical analyses. All values are depicted as mean ± standard deviation and are considered significant if p < 0.05. All data were statistically analyzed using one-way ANOVA with a Bonferroni correction, followed by Fisher’s Exact Test for comparison of two groups.

**Results**

**IGF-1 administration significantly ameliorates UUO-induced kidney injury.** UUO is a well-established renal injury model and it creates progressive renal fibrosis. IGF-1 has been shown to ameliorate renal injury and the subsequent development of renal fibrosis. Thus, we tried to reproduce these data before we addressed the underlying mechanisms. Therefore, we performed UUO on mice, while some of which received daily i.p injection of IGF-1 (UUO + IGF-1), while the other received daily i.p. injection of saline as a control (UUO). Another group of mice that received sham operation were also daily i.p. injected with saline as another control (Sham). At 3 days after UUO, we digested the kidney from some of the mice for sorting of renal epithelial cells by fluorescence-activated cell sorting (FACS). These purified renal epithelial cells were further analyzed. At 14 days after UUO, the rest of the mice were sacrificed for histology analysis to confirm the model (Fig. 1A). We used Masson trichrome staining to analyze and score for the degree of renal fibrosis regions in these mice. We found that UUO induced significant increases in kidney fibrosis, which was significantly attenuated by IGF-1, shown by representative images (Fig. 1B), and by quantification (Fig. 1C). Hence, an effect of IGF-1 against UUO-induced renal injury and fibrosis was confirmed.

**IGF-1 administration significantly decreases UUO-induced renal epithelial cell apoptosis.** Next, we examined whether IGF-1 may affect UUO-induced renal epithelial cell apoptosis. At 3 days after UUO, we digested the kidney from some of the mice for sorting of renal epithelial cells by FACS, based on expression of E-cadherin (E-cad) (Fig. 2A). These purified renal epithelial cells were further analyzed for apoptosis using a fluorescence-based apoptosis assay. We found that UUO induced significant increases in renal epithelial cell apoptosis, which was significantly attenuated by IGF-1, shown by quantification (Fig. 2B), and by representative flow charts (Fig. 2C). These data suggest that IGF-1 administration significantly decreases UUO-induced renal epithelial cell apoptosis.

**IGF-1 increases anti-apoptosis protein Bcl-2 in renal epithelial cells.** We then examined the apoptosis-associated proteins in renal epithelial cells in Sham, UUO and UUO/IGF-1-treated mice. Specifically, we found that Bcl-2 was significantly increased by IGF-1 treatment, at protein (Fig. 3A), but not mRNA (Fig. 3B) level. These data suggest that IGF-1 may reduce apoptosis of renal epithelial cells in UUO by increasing anti-apoptosis protein Bcl-2 via modulation of its protein translation.

**IGF-1 suppresses miR-429 that targets 3′-UTR of Bcl-2 mRNA to inhibit its translation in renal epithelial cells.** Since our data suggest a post-transcriptional control of Bcl-1 by IGF-1 in UUO, we hypothesized that IGF-1 may affect Bcl-2 in renal epithelial cells through miRNAs. We thus performed bioinformatics analyses for Bcl-2 targeting miRNAs and checked their expression levels in renal epithelial cells from Sham, UUO and UUO/IGF-1-treated mice. Specifically, we found that miR-429 had a binding site at the 3′-UTR of Bcl-2 mRNA ranging from 440th to 447th base site (Fig. 4A). Moreover, the levels of miR-429 in renal epithelial cells were significantly decreased in IGF-1-treated mice that received UUO (Fig. 4B). In order to figure out whether the binding of miR-429 to Bcl-2 mRNA in renal epithelial cells is functional, we either overexpressed miR-429, or inhibited miR-429 in the purified renal epithelial cells, by transfecting the cells with plasmids carrying either a miR-429-mimic (miR-429), or a miR-429 antisense (as-miR-429). The renal epithelial cells were also transfected with a plasmid carrying null sequence as a control (null). The overexpression or inhibition of miR-429 in renal epithelial cells was confirmed by RT-qPCR (Fig. 4C). MiR-429-modified renal epithelial cells were then transfected with 1 μg of Bcl-2 3′-UTR luciferase-reporter plasmid or with 1 μg of Bcl-2 3′-UTR luciferase-reporter plasmid with a site mutation between 440th to 447th base site. The luciferase activities were quantified in these cells, suggesting that the binding of miR-429 to 3′-UTR of Bcl-2 mRNA results in suppression of Bcl-2 protein translation in renal epithelial cells (Fig. 4D). Finally, Bcl-2 levels in miR-429-modified renal epithelial cells were analyzed. We found that Bcl-2 mRNA was not altered by miR-429 modification (Fig. 4E). However, Bcl-2 protein was significantly decreased in miR-429-transfected renal epithelial cells, and significantly increased in as-miR-429-transfected renal epithelial cells (Fig. 4F). These data suggest that miR-429 indeed inhibits Bcl-2 protein translation in renal epithelial cells.

**IGF-1 suppresses miR-429 through ERK1/2 signaling pathway.** In order to understand how IGF-1 suppresses miR-429 in UUO mice, we used specific inhibitors of IGF-1 downstream signaling in IGF-1-treated...
renal epithelial cells in vitro and examined their effects on Bcl-2. While no effects of inhibition of PI3k/Akt and JNK signaling pathways were detected in IGF-1-treated renal epithelial cells, inhibition of ERK1/2 signaling pathway by ERK/MAPK-p42/p44 inhibitor PD98059 (Fig. 5A) significantly abolished the effects of IGF-1 on miR-429 (Fig. 5B) and Bcl-2 activation (Fig. 5C,D). Hence, our data suggest that IGF-1 may protect tubular epithelial cells against renal injury via ERK/MAPK signaling pathway-dependent suppression of miR-429, and miR-429 inhibits Bcl-2-dependent anti-apoptosis (Fig. 6).

Discussion

Renal fibrosis is the fundamental pathway leading to end-stage renal disease. Unilateral ureteral obstruction (UUO) in the rodent is the most widely used model of renal injury-induced chronic progressive renal disease, which shares quite similar characteristics with some clinical renal disorders, including tubular atrophy, nephron loss, as well as progressive reduction in the glomerular filtration rate in chronic renal disease5–8. The reduction in proximal tubular mass appears to be the primary determinant of renal parenchymal loss following UUO, during which proximal renal tubules undergo oxidant injury and cell apoptosis, resulting in tubular collapse and decomposition. Here we used a mouse UUO model in our study. The exact protocol of ligation may result in different levels of injury to the kidney. We used a 14-day protocol, which allows us to detect enough remaining kidney mass in our study, as a quality control for the model. The renal epithelial cells were isolated at day 3 after UUO, since the cell injury occurs in the quite early stage. This time point allows us to best characterize the injured renal epithelial cells.
Figure 2. IGF-1 administration significantly decreases UUO-induced renal epithelial cell apoptosis. (A) At 3 days after UUO, we digested the kidney from some of the mice for sorting of renal epithelial cells by FACS, based on expression of E-cadherin (E-cad). These purified renal epithelial cells were further analyzed for apoptosis. (B,C) Renal epithelial cell apoptosis was analyzed using fluorescence-based apoptosis assay, shown by quantification (B) and by representative flow charts (C). N = 10. *p < 0.05.

Figure 3. IGF-1 increases anti-apoptosis protein Bcl-2 in renal epithelial cells. (A,B) Bcl-2 was significantly increased by IGF-1 treatment, at protein level by Western blot (A), but not at mRNA level by RT-qPCR (B). N = 10. NS: non-significant. *p < 0.05.
Figure 4. IGF-1 suppresses miR-429 that targets 3′-UTR of Bcl-2 mRNA to inhibit its translation in renal epithelial cells. (A) Bioinformatics analyses for Bcl-2 targeting miRNAs showed that miR-429 had a binding site at the 3′-UTR of Bcl-2 mRNA ranged from 440th to 447th base site. (B) The levels of miR-429 in renal epithelial cells were significantly decreased in IGF-1-treated mice that received UUO. (C) We either overexpressed miR-429, or inhibited miR-429 in the purified renal epithelial cells, by transfecting the cells with plasmids carrying either a miR-429-mimic (miR-429), or a miR-429 antisense (as-miR-429). The renal epithelial cells were also transfected with a plasmid carrying null sequence as a control (null). The overexpression or inhibition of miR-429 in renal epithelial cells was confirmed by RT-qPCR. (D) MiR-429-modified renal epithelial cells were then transfected with 1 μg of Bcl-2 3′-UTR luciferase-reporter plasmid or with 1 μg of Bcl-2 3′-UTR luciferase-reporter plasmid with a site mutation between 440th to 447th base site. The luciferase activities were quantified in these cells. (E,F) Bcl-2 mRNA (E) and protein (F) in miR-429-modified renal epithelial cells. N = 10. *p < 0.05.
Figure 5. **IGF-1 suppresses miR-429 through ERK1/2 signaling pathway.** Renal epithelial cells received 100 ng/ml IGF-1 (and) 10 μmol/l ERK/MAPK-p42/p44 inhibitor PD98059. (A) Western blot for phosphorylation of ERK1/2. (B) RT-qPCR for miR-429. (C) RT-qPCR for Bcl-2. (D) Western blot for Bcl-2. N = 5. *p < 0.05.

Figure 6. **Schematic of the model.** IGF-1 may protect tubular epithelial cells against renal injury via ERK/MAPK signaling pathway-dependent suppression of miR-429, and miR-429 inhibits Bcl-2-dependent anti-apoptosis.
Prevention of renal epithelial cell apoptosis thus appears to be critical for preservation of kidney function after renal injury. Due to oxidative stress, the mitochondrial dysfunction by accumulation of intracellular reactive oxygen species (ROS) has been associated with apoptosis. As a well-known anti-apoptotic gene, Bcl-2 stabilizes mitochondria, blocks the classic apoptotic pathways, and suppresses autophagy through binding with Beclin 1[15,17]. In the current study, we found that Bcl-2 was controlled by IGF-1 in UUO, as a major mechanism for the renal epithelial cells to resist the injury and survive. However, the Bcl-2 were affected by IGF-1 at protein level, but not mRNA level, suggesting that Bcl-2 was regulated by IGF-1 at post-transcriptional level. It has been shown that Bcl-2 phosphorylation and subsequent proteasome-Dependent degradation could be regulated in some situation[26–31]. Moreover, Bcl-2 has been shown to be regulated by miRNAs[15,24,25,32–34]. Specifically, miR-429 has been shown to suppress Bcl-2 protein translation in gastric cancer cells[25] and endothelial cells[34]. However, it is unknown whether miR-429 is a downstream target of IGF-1 and whether miR-429 has a similar effect on Bcl-2 in renal epithelial cells[6–11]. Indeed, post-transcriptional regulators of gene expression, such as miRNAs are increasingly recognized as differentially regulating protein expression and playing a key role in the pathological processes in the renal diseases. The revealed miRNAs that were regulated by IGF-1 are miR-1, miR-103 and miR-133a[35–38]. To the best of our knowledge, the current study was the first report showing that miR-429 is regulated by IGF-1, and in an ERK/MAPK-p42/p44-signaling pathway-dependent manner.

Here, by sequence matching using bioinformatics analyses, we found quite a few of candidate miRNAs that target Bcl-2, including miR-429, miR-30, miR-22, miR-25, miR-32, miR-92, miR-363, miR-367, miR-99, miR-27, miR-128, etc. Among all these miRNAs, we specifically detected a significant change in miR-429 by UUO and IGF-1, compared to control in renal epithelial cells. Hence, targeting suppression of Bcl-2 by miR-429 was analyzed and confirmed. All the current studies have used primary renal epithelial cells. Thus, a possibility of the results to be cell-line-dependence could be excluded.

UUO injury model induces renal epithelial proliferation as part of the progression to fibrosis. Here, we showed that Bcl-2 in renal epithelial cells upregulated after UUO, as a protective function of the cells to counteract apoptotic cell death. Of note, cell apoptosis, activation of survival machinery (Bcl-2), cell proliferation and transformation (e.g. epithelial-mesenchymal transition to lead to tissue remodeling) are all typical characteristics for inflammation and are often associated with each other.

Our data showed that Bcl-2 expression in UUO is significantly higher than in sham group, while miR-429 is highly expressed in UUO than in sham. For this higher levels of both Bcl-2 and miR-429 in renal epithelial cells after UUO compared to sham, we feel that UUO induces kidney injury and Bcl-2 is activated in kidney epithelial cells to counteract cell death. Hence, Bcl-2 increases after UUO. However, endogenous miR-429 expression may be a part of the negative regulatory loop of the Bcl-2 in kidney epithelial cells under stress. When the cells are not insulted, their Bcl-2 levels are low and miR-429 levels are also low. When Bcl-2 is activated after UUO, the miR-429 may be activated to counteract the increases in Bcl-2. Moreover, when IGF-1 is administrated, it may decrease miR-429 levels, resulting in loss of control of increases in Bcl-2.

However, since miR-429 is not responsible for the control of Bcl-2 levels in UUO vs sham, and the Bcl-2 level changes in UUO also appeared to posttranscriptional, we think that another posttranscriptional control of Bcl-2 levels by factors other than miR-429 may be present in kidney epithelial cells after UUO, possibly the control of protein degradation of Bcl-2. Future studies may address these questions.

To summarize, we propose a model to explain the mechanisms underlying protective effects of IGF-1 on renal epithelial cells during injury. IGF-1 may protect tubular epithelial cells against renal injury via ERK/MAPK signaling pathway-dependent suppression of miR-429, and miR-429 inhibits Bcl-2-dependent anti-apoptosis.

References

1. Pan, B., Liu, G., Jiang, Z. & Zheng, D. Regulation of renal fibrosis by macrophage polarization. Cell Physiol Biochem 35, 1062–1069, doi: 10.1159/000373932 (2015).

2. Shen, B., Liu, X., Fan, Y. & Qiu, J. Macrophages Regulate Renal Fibrosis Through Modulating TGFbeta Superfamily Signaling. Inflammation 37, 2076–2084, doi: 10.1007/s11195-014-1944-y (2014).

3. Liu, Q. et al. Renal Denervation Findings on Cardiac and Renal Fibrosis in Rats with Isoproterenol Induced Cardiomyopathy. Scientific reports 5, 18852, doi: 10.1038/srep18852 (2015).

4. Yao, Y., Pinzi, V., Bourhis, J. & Deutsch, E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor. J Clin Invest 128, 1261–1273 (2003).

5. Sato, M., Muragaki, Y., Saika, S., Roberts, A. B. & Oshima, A. Targeted disruption of TGFbeta1/Smad signaling pathway promotes renal fibrosis in mice. J Am Pathol 163, 1261–1273 (2003).

6. Tao, Y., Pinzi, V., Bourhis, J. & Deutsch, E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer. Nat Clin Pract Oncol 4, 591–602, doi: 10.1038/ncponc0934 (2007).

7. Ewing, G. P. & Goff, L. W. The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma. Clin Colorectal Cancer 9, 219–223, doi: 10.3816/CACC.2010.n.032 (2010).

8. Ewing, G. P., Goff, L. W. & Grobe, L. W. The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma. Clin Colorectal Cancer 9, 219–223, doi: 10.3816/CACC.2010.n.032 (2010).

9. Tognon, C. E. & Sorensen, P. H. Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy. Expert Opin Ther Targets 16, 33–48, doi: 10.1517/14728222.2011.638626 (2012).

10. Pan, B., Liu, G., Jiang, Z. & Zheng, D. Regulation of renal fibrosis by macrophage polarization. Cell Physiol Biochem 35, 1062–1069, doi: 10.1159/000373932 (2015).

11. Shen, B., Liu, X., Fan, Y. & Qiu, J. Macrophages Regulate Renal Fibrosis Through Modulating TGFbeta Superfamily Signaling. Inflammation 37, 2076–2084, doi: 10.1007/s11195-014-1944-y (2014).

12. Liu, Q. et al. Renal Denervation Findings on Cardiac and Renal Fibrosis in Rats with Isoproterenol Induced Cardiomyopathy. Scientific reports 5, 18852, doi: 10.1038/srep18852 (2015).

13. Tao, Y., Pinzi, V., Bourhis, J. & Deutsch, E. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway—therapeutic perspectives in cancer. Nat Clin Pract Oncol 4, 591–602, doi: 10.1038/ncponc0934 (2007).

14. Ewing, G. P. & Goff, L. W. The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma. Clin Colorectal Cancer 9, 219–223, doi: 10.3816/CACC.2010.n.032 (2010).

15. Tognon, C. E. & Sorensen, P. H. Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy. Expert Opin Ther Targets 16, 33–48, doi: 10.1517/14728222.2011.638626 (2012).

16. Ingwall, J. S. & Seldin, D. M. Hypoxia and the kidney: a new perspective. Kidney Int 4, 421–432, doi: 10.1038/ki.1993.151 (1993).

17. Tog, J. E. & Seldin, D. M. Hypoxia and the kidney: a new perspective. Kidney Int 4, 421–432, doi: 10.1038/ki.1993.151 (1993).

18. Tog, J. E. & Seldin, D. M. Hypoxia and the kidney: a new perspective. Kidney Int 4, 421–432, doi: 10.1038/ki.1993.151 (1993).

19. Tog, J. E. & Seldin, D. M. Hypoxia and the kidney: a new perspective. Kidney Int 4, 421–432, doi: 10.1038/ki.1993.151 (1993).
15. Karim, C. B. et al. Structural Mechanism for Regulation of Bcl-2 protein Noxa by phosphorylation. *Scientific reports* 5, 14557, doi: 10.1038/srep14557 (2015).

16. Pan, W. et al. Functional BCL-2 regulatory genetic variants contribute to susceptibility of esophageal squamous cell carcinoma. *Scientific reports* 5, 11833, doi: 10.1038/srep11833 (2015).

17. Zhang, Y. et al. Hydrogen sulfide attenuates the recruitment of CD11b(+)Gr-1(+) myeloid cells and regulates Bax/Bcl-2 signaling in myocardial ischemia injury. *Scientific reports* 4, 4774, doi: 10.1038/srep04774 (2014).

18. Morishita, Y. et al. siRNAs targeted to Smad3 prevent renal fibrosis in vivo. *Scientific reports* 4, 6424, doi: 10.1038/srep06424 (2014).

19. Di Leva, G. & Croce, C. M. miRNA profiling of cancer. *Curr Opin Genet Dev* 23, 3–11, doi: 10.1016/j.gde.2013.01.004 (2013).

20. Pereira, D. M., Rodrigues, P. M., Borrinho, P. M. & Rodrigues, C. M. Delivering the promise of miRNA cancer therapeutics. *Drug Discov Today* 18, 282–289, doi: 10.1016/j.drudis.2012.10.002 (2013).

21. Mei, Q., Li, F., Quan, H., Liu, Y. & Xu, H. Busulfan inhibits growth of human osteosarcoma through miR-200 family microRNAs in vitro and in vivo. *Cancer Sci* 105, 755–762, doi: 10.1111/cas.12436 (2014).

22. Wang, F., Xiao, W., Sun, J., Han, D. & Zhu, Y. MiRNA-181c inhibits EGFR-signaling-dependent MMP9 activation via suppressing Akt phosphorylation in glioblastoma. *Tumour Biol* 35, 8653–8658, doi: 10.1007/s13277-014-2131-6 (2014).

23. Liu, G., Jiang, C., Li, D., Wang, R. & Wang, W. MiRNA-34a inhibits EGFR-signaling-dependent MMP7 activation in gastric cancer. *Tumour Biol* 35, 9801–9806, doi: 10.1007/s13277-014-2273-6 (2014).

24. Zhang, T. et al. Atherosclerosis-Associated Endothelial Cell Apoptosis by MiR-429-Mediated Down Regulation of Bcl-2. *Cell Physiol Biochem* 37, 1421–1430, doi: 10.1159/000438511 (2015).

25. Zha, P. et al. MiR-429 Induces Gastric Carcinoma Cell Apoptosis Through Bcl-2. *Cell Physiol Biochem* 37, 1572–1580, doi: 10.1159/000438524 (2015).

26. Wang, Y. et al. MiR-429 up-regulation induces apoptosis and suppresses invasion by targeting Bcl-2 and SP-1 in esophageal carcinoma. *Cellular oncology* 36, 385–394, doi: 10.1007/s13402-013-0144-6 (2013).

27. Wen, J. G. Partial unilateral ureteral obstruction in rats. *Neurol Urodyn* 21, 231–250 (2002).

28. Martina, M. N., Bandapalle, S., Rabb, H. & Hamad, A. R. Isolation of double negative alphabeta T cells from the kidney. *J Vis Exp* doi: 10.3791/51192 (2014).

29. Zhang, Y. X. et al. Ursolic acid overcomes Bcl-2-mediated resistance to apoptosis in prostate cancer cells which is mediated by microRNA-1. *Biochem Biophys Res Commun* 548–552, doi: 10.1016/j.bbrc.2008.09.025 (2008).

30. Pan, W. et al. Functional BCL-2 regulatory genetic variants contribute to susceptibility of esophageal squamous cell carcinoma. *Cell Physiol Biochem* 83–95, doi: 10.1111/j.1582-4934.2011.01307.x (2012).

31. Wilk, K. & Ratafia, L. A. Bcl-2 phosphorylation and proteasome-mediated degradation at the endoplasmic reticulum. *J Biol Chem* 281, 101–111 (2006).

32. Zhu, M. et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. *J Biol Chem* 285, 21496–21507, doi: 10.1074/jbc.M109.033377 (2010).

33. Liao, Y. et al. IGF-1 deficiency resists cardiac hypertrophy and myocardial contractile dysfunction: role of miR-133a. *J Cell Mol Med* 14, 8653–8658, doi: 10.1111/j.1582-4934.2011.01307.x (2012).

34. Wang, X. & Wang, Y. Ginsenoside Rh2 Mitigates Pediatric Leukemia Through Suppression of Bcl-2 in Leukemia Cells. *Cell Physiol Biochem* 37, 641–650, doi: 10.1159/000343083 (2015).

35. Li, Y., Shen, Y., Heng, W. et al. IGF-1 promotes oxidative stress-induced apoptosis in induced pluripotent stem cells which is mediated by microRNA-1. *Biochem Biophys Res Commun* 426, 615–619, doi: 10.1016/j.bbrc.2012.08.139 (2012).

36. Hua, Y., Zhang, Y. & Ren, J. IGF-1 deficiency resists cardiac hypertrophy and myocardial contractile dysfunction: role of microRNA-1 and microRNA-133a. *J Cell Mol Med* 16, 83–95, doi: 10.1111/j.1749-6632.2011.01307.x (2012).

37. Liao, Y. & Sonnendal, B. Global microRNA characterization reveals that miR-103 is involved in IGF-1 stimulated mouse intestinal cell proliferation. *PLoS One* 5, e12976, doi: 10.1371/journal.pone.0012976 (2010).

38. Yu, Y. et al. Glucose induces apoptosis of cardiomyocytes via microRNA-1 and IGF-1. *Biochem Biophys Res Commun* 376, 548–552, doi: 10.1016/j.bbrc.2008.09.023 (2008).

**Author Contributions**

The study was conceived and designed by Z.W. and S.P. Acquisition and analysis of data was performed by Z.W., Y.Y., L.N., A.F. and S.P. Z.W. and S.P. interpreted the data. S.P. drafted the article, and all authors revised the article and approved the final version to be published.

**Additional Information**

**Competing financial interests:** The authors declare no competing financial interests.

**How to cite this article:** Wu, Z. et al. IGF-1 protects tubular epithelial cells during injury via activation of ERK/MAPK signaling pathway. *Sci. Rep.* 6, 28066; doi: 10.1038/srep28066 (2016).